AI
Friday, July 01, 2016 1:28:07 PM
AstraZeneca Ends European Licensing Pact With Valeant
AstraZeneca PLC (AZN. LN) has terminated its European licensing pact for skin medicine brodalumab with Canadian drugmaker Valeant Pharmaceuticals International Inc. (VRX. T) and has instead granted the license to Danish firm LEO Pharma A/S, in a bid to further broaden the launch market for the experimental drug.
The British pharmaceutical giant said Friday that it had mutually agreed to terminate the European licensing pact for brodalumab with an affiliate of Valeant.
It added, however, that Valeant will continue to lead the development and commercialization of the drug in the U.S. and certain other markets as per the initial agreement entered in September 2015.
Valeant, which is currently being probed by multiple U.S. regulators in connection with drug pricing and dealings with distributors, said separately that the termination will help the company to focus on the U.S. market.
It also said AstraZeneca will pay an undisclosed upfront payment and certain milestone-related payments as a consideration for the termination.
AstraZeneca PLC (AZN. LN) has terminated its European licensing pact for skin medicine brodalumab with Canadian drugmaker Valeant Pharmaceuticals International Inc. (VRX. T) and has instead granted the license to Danish firm LEO Pharma A/S, in a bid to further broaden the launch market for the experimental drug.
The British pharmaceutical giant said Friday that it had mutually agreed to terminate the European licensing pact for brodalumab with an affiliate of Valeant.
It added, however, that Valeant will continue to lead the development and commercialization of the drug in the U.S. and certain other markets as per the initial agreement entered in September 2015.
Valeant, which is currently being probed by multiple U.S. regulators in connection with drug pricing and dealings with distributors, said separately that the termination will help the company to focus on the U.S. market.
It also said AstraZeneca will pay an undisclosed upfront payment and certain milestone-related payments as a consideration for the termination.
My post is for Your Eyes only and my entertainment
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
